Patients’ eligibility for the commencement of antiviral therapy is dependent on key factors such as age, HBV viral load, serum alanine transaminase (ALT) levels, aspartate to platelet ratio index (APRI), clinical evidence of liver cirrhosis, comorbidities such as diabetes mellitus, and concomitant hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV) coinfections [11–13]. This evidence concerns the gene GPT and cirrhosis of liver.